Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
aka SIERRA
A phase 3 trial of Iomab-B run by Actinium Pharmaceuticals, active.
Overview
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia is a phase 3 interventional study registered as NCT02665065 by Actinium Pharmaceuticals, with 153 participants enrolled, started 2016-06. Conditions listed: Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute. No results are recorded here; the registry entry is the source.
Setting
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplant Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase
Phase 3
Sponsor
Actinium Pharmaceuticals
Registry
Enrolled
153 enrolled
Similar pages
not linked directly; found by shared links- TechnologyRadio-antibody & radio-ADC
Shares Iomab-B, Actinium Pharmaceuticals.
drugs
1Phase 3Radioimmunotherapy conditioning agent (anti-CD45 antibody labelled with iodine-131)